Navigation Links
GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder
Date:12/20/2007

pag 30mg (13%), 50mg (10%), 75mg (21%) and placebo (21%) arms. At least one AE was reported in 47%, 47% and 61% of patients in the eltrombopag 30mg, 50mg and 75mg groups respectively, compared with 59% in the placebo arm.

Phase II study results were published in the November 29, 2007 issue of New England Journal of Medicine.

About Idiopathic Thrombocytopenic Purpura There are estimated to be between 50,000-100,000 individuals diagnosed with chronic ITP in the U.S.(5) People with chronic ITP often bleed from small blood vessels causing bruises, nosebleeds or even fatal gastrointestinal or intra cerebral bleeds.(1)

About PROMACTA (eltrombopag)

Eltrombopag is an oral, non-peptide thrombopoietin receptor agonist that has been shown in pre-clinical research and clinical trials to stimulate the proliferation and differentiation of megakaryocytes, the bone marrow cells that give rise to blood platelets. Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals (Nasdaq: LGND). It is being developed by GlaxoSmithKline. Eltrombopag is an investigational compound that has not received regulatory approval in any market for any indication at this time.

About GlaxoSmithKline

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline at http://www.gsk.com.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Refor
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. GlaxoSmithKline Responds to JAMA Articles
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results
4. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
5. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
6. GlaxoSmithKline Aids California Fire Relief Efforts
7. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
8. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
9. Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
10. GlaxoSmithKline Presents Innovative Neuroscience Pipeline
11. GlaxoSmithKline Receives FDA Complete Response Letter for Cervical Cancer Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... With the swift industrial development of ... as smart phones, tablets and PDAs, a complete change ... devices are viewed these days. From only being used ... a mode for creating and delivering content while on ... , The complete makeover of this (mobile) ...
(Date:9/18/2014)... County, NY (PRWEB) September 18, 2014 ... Westchester residents, community advocates, and volunteers supported United ... annual “Best Chefs and Fine Wines” event Monday, Sept. ... United Way’s health initiatives in Westchester and Putnam, such ... obesity, and steering teens away from risky behaviors like ...
(Date:9/18/2014)... common Asian spice and cancer-hampering molecules show promise ... of the lung,s lining often linked to asbestos. ... Georg-Speyer-Haus in Frankfurt, Germany, demonstrate that application of ... cancer-inhibiting peptides increase levels of a protein inhibitor ... Their findings appeared in the Aug. 14 online ...
(Date:9/18/2014)... NC (PRWEB) September 18, 2014 October ... also Domestic Violence Awareness Month. And the Centers for ... tells a scary story. , According to the CDC ... fourth of men in the U.S. experience some form ... intimate relationship. The same survey shows that about half ...
(Date:9/18/2014)... 2014 With the arrival of subsequent-entry biologics ... Society released new resources to educate stakeholders on their potential ... guide SEB use, and patients must be well informed when ... Click here for an infographic and an expert video ... here for The Arthritis Society’s position paper on SEBs. ...
Breaking Medicine News(10 mins):Health News:Transparency Market Research: M-health Market Study 2018 2Health News:Transparency Market Research: M-health Market Study 2018 3Health News:Transparency Market Research: M-health Market Study 2018 4Health News:United Way Celebrates “Best Chefs and Fine Wines” at Sold-Out Culinary Event 2Health News:United Way Celebrates “Best Chefs and Fine Wines” at Sold-Out Culinary Event 3Health News:Curcumin, special peptides boost cancer-blocking PIAS3 to neutralize STAT3 in mesothelioma 2Health News:Curcumin, special peptides boost cancer-blocking PIAS3 to neutralize STAT3 in mesothelioma 3Health News:What you should know about domestic violence 2Health News:What you should know about domestic violence 3Health News:What you should know about domestic violence 4Health News:What you should know about domestic violence 5Health News:Subsequent-entry biologics set to alter the arthritis treatment landscape 2
... Volumizing ... ... of the eyes change in generally predictable ways: the skin thins and becomes less elastic, ... eyes appear more prominent. While surgery has long been the accepted standard and offers ...
... , COLD SPRING HARBOR, N.Y., Aug. 17 ... Doctors Laboratory (TDL), the largest independent provider of clinical laboratory ... the world,s first hand-held, non-contact vein illumination device, to the ... locate veins for blood draw (venipuncture) by projecting a pattern ...
... , ALBANY, N.Y., Aug. 17 The ... August 17, 2009, is an Air Quality Action Day, a ... such as children, seniors and people with asthma and other ... pollution. The alert is issued for the New York downstate ...
... , , MCLEAN, Va., Aug. 17 ... His Cookie Helped 500,000 People Lose Weight Fast (2009, Hyde ... at CookieDiet.com, Amazon.com, Borders.com, and BN.com; at Barnes & Noble stores ... Biggest Bookstore, and Coles. , , "Dr. Siegal,s ...
... Finding will help predict patient response to therapy, researchers say ... that predicts a patient,s response to hepatitis C treatments has ... a single letter change -- a C instead of a ... gene, according to the Duke University Medical Center team. They ...
... , PRINCETON, N.J., Aug. 17 Derma ... a provider of advanced wound care products, reports results today for the second quarter ... for second quarter and six months ended June 30, 2009: , , ... to $664,766 in second quarter 2009, versus $295,315 in 2008. For the six months ...
Cached Medicine News:Health News:Nonsurgical Technique Can Take Years Off the Appearance of Aging Eyes 2Health News:Nonsurgical Technique Can Take Years Off the Appearance of Aging Eyes 3Health News:AccuVein Sells Multiple AV300s to First European Customer 2Health News:Air Quality Action Day Declared for Monday, August 17, 2009 2Health News:Dr. Siegal's Cookie Diet Book Available at Amazon, Barnes & Noble, and Indigo Books 2Health News:Dr. Siegal's Cookie Diet Book Available at Amazon, Barnes & Noble, and Indigo Books 3Health News:Dr. Siegal's Cookie Diet Book Available at Amazon, Barnes & Noble, and Indigo Books 4Health News:Genetic Discovery May Improve Hepatitis C Treatment 2Health News:Derma Sciences Reports Second Quarter 2009 Results 2Health News:Derma Sciences Reports Second Quarter 2009 Results 3Health News:Derma Sciences Reports Second Quarter 2009 Results 4Health News:Derma Sciences Reports Second Quarter 2009 Results 5Health News:Derma Sciences Reports Second Quarter 2009 Results 6Health News:Derma Sciences Reports Second Quarter 2009 Results 7Health News:Derma Sciences Reports Second Quarter 2009 Results 8
(Date:9/18/2014)... and LONDON , ... era for biopharmaceutical companies. Competition for innovation, increasing ... to keep up with the fast-changing environment are ... influence clinical trials, and clinical trial costs continue ... patient recruitment. Studies conducted by industry ...
(Date:9/18/2014)... , Sept. 18, 2014  ADM Tronics ... DeNovi , Ph.D. to its corporate Advisory Board ... an instructor at the Harvard Medical School and ... Rome.  He received his Masters degree in Electronics ... Systems from the University of Bologna. After spending a ...
(Date:9/18/2014)... , Sept. 18, 2014 MiMedx Group, ... developer, processor and marketer of patent protected regenerative ... announced today that it has entered into a ... MiMedx will provide its dehydrated human amnion/chorion membrane ... non- exclusively on a private label basis. ...
Breaking Medicine Technology:Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3
... and secondary endpoints of,study; no negative drug-drug ... CAMBRIDGE, Mass., June 12, 2007 /PRNewswire-FirstCall/ -- ... phase II study,designed to evaluate triple combination ... candidate for the,treatment of hepatitis C, pegylated ...
... II Study Demonstrates Significant,Additional Improvement for Patients ... /PRNewswire-FirstCall/ --,Indevus Pharmaceuticals, Inc. today announced that ... for pagoclone in persistent,developmental stuttering will be ... the New Clinical Drug Evaluation Unit (NCDEU), ...
Cached Medicine Technology:Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 2Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 3Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 4Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 5Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 6Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 2Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 3Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 4Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 5Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 6Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 7Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 8Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 9
Resorbable fixation system 1.5/2.0....
... Sonomed-315 is intended for visualization of the ... midline shifts in the brain, evaluation of ... to use, the Sonomed-315 offers quick and ... allows to identify the anatomic structures of ...
... cost, low volume alternative. Whole blood is drawn ... from whole blood by centrifugation in a standard ... Cebus single use cartridge. The cartridge is then ... the concentrating process. Finally, the cartridge is spun ...
Exclusive oxidized regenerated cellulose technology. The only oxidized regenerated cellulose hemostat line, surgicel absorbable hemostat delivers a unique combination of effectiveness, absorbability,...
Medicine Products: